Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics, Inc. - Common Stock (NQ: ELTX )

7.900 -0.050 (-0.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Elicio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023
ELTX stock results show that Elicio Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P
--News Direct-- 
Via News Direct
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
--News Direct-- 
Via News Direct
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
A clinical-stage biotechnology company has published promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR).    
Via Benzinga
First Patient Dosed In Phase 2 Study Of Elicio Therapeutics' ELI-002 7P
A phase 2 trial by a clinical-stage biotechnology company is kicking into full gear.  
Via Benzinga
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002
--News Direct-- 
Via News Direct
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002
Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are the second and 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
From Elicio Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
A look at five stocks seeing increased attention from investors. 
Via Benzinga
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
From Elicio Therapeutics Inc.
Via GlobeNewswire
Unity Layoffs 2024: What to Know About the Latest U Job Cuts
Unity layoffs are on the way as the video game software company reveals plans to cut 1,800 jobs to focus on its core business. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?
Cyclacel Pharmaceuticals stock is slipping on Tuesday after shares of CYCC rallied on Monday alongside it regaining Nasdaq compliance. 
Via InvestorPlace
Why Is Grifols (GRFS) Stock Down 38% Today?
Grifols stock is falling hard as investors sell GRFS shares after the company was hit with a short report from Gotham City Research. 
Via InvestorPlace
Why Is Elicio Therapeutics (ELTX) Stock Up 11% Today?
Elicio Therapeutics stock is up with heavy trading of ELTX shares are posting positive preliminary results from a Phase 1 clinical trial. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning! 
Via InvestorPlace
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
From Elicio Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.